Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia

doi:10.4254/wjh.v2.i5.180

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2213)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

201

HTML

1932

Tables (1-1)

Sum=2213

May 27, 2010 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Hepatol. May 27, 2010; 2(5): 180-184
Published online May 27, 2010. doi: 10.4254/wjh.v2.i5.180

Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia

Hussain Issa

Hussain Issa, Division of Gastroenterology, Department of Internal Medicine, King Fahad Specialist Hospital, Dammam, Sayhat 7312-32437, Saudi Arabia

Author contributions: Issa H contributed solely to this paper.

Correspondence to: Hussain Issa, MD, Division of Gastroenterology, Department of Internal Medicine, King Fahad Specialist Hospital, Dammam, PO Box 4012, Sayhat 7312-32437, Saudi Arabia. hussain31911@yahoo.com

Telephone: +966-3-8372138

Received: January 16, 2010
Revised: May 6, 2010
Accepted: May 13, 2010
Published online: May 27, 2010

Core Tip